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Objectives. This study sought to compare the short- and long-
term outcomes of elderly patients undergoing coronary artery
stenting with those of younger patients and to determine the
long-term clinical outcome and survival of elderly patients post
stent implantation.
Background. Elderly patients undergoing coronary revascular-
ization are considered a high-risk group. Few data exist that relate
the results of stenting in treating coronary artery disease in the
elderly population.
Methods. All elderly patients >275 years of age who underwent
coronary artery stenting between March 1993 and July 1997 (n 5
137) at our center were compared to the patients <75 who
underwent coronary artery stenting during the same time period
(n 5 2,551). Long-term clinical follow-up and survival were
determined for the elderly group.
Results. Elderly patients presented with lower ejection fractions
(54% vs. 58%, p 5 0.0001), more unstable angina (47% vs. 28%,
p 5 0.0001), and more multivessel disease (78% vs. 62%, p 5
0.0001) than younger patients. These older patients had higher
rates of procedure related complications including procedural
myocardial infarction (MI) (2.9% vs. 1.7%, p 5 0.2), emergency
CABG (3.7% vs. 1.4%, p 5 0.04), and death (2.2% vs. 0.12%, p 5
0.0001). Angiographic follow-up, obtained in both groups, demon-
strated significantly higher restenosis rates in the elderly versus
younger patients (47% vs. 28%, p 5 0.0007). Longer term clinical
follow-up, which was obtained only in the elderly group, showed
that at a mean follow-up period of 12 months post coronary
stenting, elderly survival free from death, MI, revascularization
and angina was 54% and that their overall survival was 91%.
Subanalysis of the elderly patients who died showed much higher
incidence of combined unstable angina (80%), prior MI (60%),
lower ejection fraction (46%), multivessel disease (100%) and
complex lesions (100%) than the overall group.
Conclusions. Elderly patients who undergo coronary artery
stenting have significantly higher rates of procedural complica-
tions and worse six month outcomes than younger patients,
especially those who present with combined unstable angina,
history of MI, EF < 50%, multivessel disease and complex lesions.
Overall survival in the elderly population at 12 months postcoro-
nary artery stenting was 91% and event-free survival was 54%.
(J Am Coll Cardiol 1998;32:577–83)
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The elderly comprise the fastest growing segment of the
population. In 1990, the U.S. census estimated that there were
.31 million persons over the age of 65, 25% of which had
reported symptomatic coronary artery disease. The number of
elderly are expected to increase by 65% by the year 2020 (1).
Compared to the general population, elderly patients un-
dergoing coronary revascularization have traditionally been
more likely to present with more: complex lesions, unstable
angina, comorbid conditions and lower ejection fractions (1–
10). At least in part due to these facts elderly patients have
traditionally had higher rates of procedure related death and
complications when undergoing percutaneous transluminal
coronary angioplasty (PTCA) or coronary artery bypass graft-
ing (CABG) (4–23). Despite these problems, the rates of
PTCA and CABG among the elderly, between 1987 and 1990,
increased by 55% and 18%, respectively.
With the advent of procedural modification, allowing the
elimination of anticoagulation, coronary artery stenting has
come to widespread use (24–27), including in the elderly. But
do the advantages that stenting has afforded the general
population translate to the elderly population with comparable
procedure-related complications and long-term outcome? The
present study was designed to investigate the impact of stenting
in treating coronary artery disease in our elderly population
$75 years of age and examines the period of time from March
1993 through July 1997.
Methods
Study patients. The study included 2,688 consecutive pa-
tients who underwent coronary artery stenting at the Centro
Cuore Columbus, Milan, Italy, between March 30, 1993, and
July 2, 1997. All patients treated with intracoronary stents
during this time period were included in our analysis, divided
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into two cohort groups: 2,551 persons ,75 years of age
(younger cohort) and 137 persons $75 years of age (elderly
cohort).
Stent implantation procedure. Before stent implantation
procedure, all patients received aspirin 325 mg to 500 mg. A
10,000 unit bolus of heparin was given after sheath insertion;
thereafter, heparin boluses were administered during the
procedure as needed to maintain an activated clotting time
$250 s. The Palmaz-Schatz stent was used in 42% of the
lesions, the NIR stent in 12%, the AVE stents in 7% and the
Gianturco-Roubin stent in 7%. In the remaining patients other
types of slotted tube or coil stents were used. Stents were either
hand crimped on a balloon or premounted on a delivery
system. After stent deployment, further dilatations were per-
formed using high-pressure balloon inflations ($14 atm). Since
April 1993 stents have been placed with the utilization of
intravascular ultrasound in the majority of cases. With the
introduction of intravascular ultrasound guided coronary stent-
ing, patients who met optimal stenting criteria did not receive
any heparin or oral anticoagulant agents after the procedure.
Only 3.2% of patients ,75 and 1.7% of patients $75 received
any type of anticoagulation therapy during this time period (no
patients received dextran or dipyridamole). Ticlopidine
(250 mg twice daily) was given for a period of one month and
aspirin (325 mg daily) continued indefinitely.
Indications for stenting and their definitions were per-
formed as previously reported (27). The use of .1 stent per
lesion or per patient was considered multiple stenting. Each
stent was counted as one stent except the short Palmaz-Schatz
stents and the 4 or 8 mm Micro stents, which were counted as
half stents.
Angiographic analysis. Coronary angiograms were ob-
tained in a routine fashion. Patients received intracoronary
isosorbide dinitrate before initial and postprocedural angio-
grams to achieve maximal vasodilatation. Vessel and lesion
measurements were obtained using a computerized quantita-
tive analysis system (QCA-CMS Version 3.0, MEDIS) accord-
ing to previously described and validated edge detection
algorithms using the catheter as the object of calibration (28).
The following measurements were obtained both preinterven-
tion and poststent placement: reference vessel diameters,
minimal lumen diameter, percent diameter stenosis and lesion
length. Each stenotic segment was evaluated for the presence
or absence of calcium and thrombus. Lesions were character-
ized according to the modified American Heart Association/
American College of Cardiology classification (29).
Follow-up. Clinical follow-up was obtained when patients
were seen at the outpatient clinic or by direct telephone
interview. Adjunctive information was obtained from the re-
ferring physician. Event-free survival upon clinical follow-up
was defined as free from death, myocardial infarction (MI),
revascularization or angina. Survival curves were generated
taking into account all elderly patients who underwent stent
implantation and all related deaths from the time of stent
implantation. Angina symptoms were characterized according
to the Canadian Cardiovascular Society classification. For
patients who had clinical events, clinical follow-up ended at the
time of the event. Angiographic follow-up was routinely sched-
uled at 5 to 6 months postprocedure for all patients with a
successful procedure who had had their procedure $5 months
prior to this analysis and had not undergone CABG during this
period. Restenosis was defined as $50% diameter stenosis by
angiography on follow-up. Diffuse restenosis was defined as a
restenotic lesion .10 mm in length (30,31).
Definitions. Procedure success was defined as #20% resid-
ual stenosis in the target lesion poststent implantation without
the occurrence of myocardial infarction, urgent coronary ar-
tery bypass graft surgery or death. Complete revascularization
was achieved when there was no residual stenosis $70% in any
major coronary artery or their large branches unless a bypass
graft fed the territory distal to a diseased segment. Clinical
events were defined as death from any cause, coronary artery
bypass surgery, myocardial infarction (Q wave or nonQ wave)
repeat angioplasty and vascular complications. Q wave myocar-
dial infarction was diagnosed when there were new pathologic
Q waves on electrocardiogram accompanied by an elevation in
creatinine kinase levels to twice the normal level. A non-Q
wave myocardial infarction was diagnosed when an elevation of
the creatinine kinase to twice normal levels occurred without
the development of Q waves. Vascular complications were
defined as the occurrence of pseudoaneurysm, bleeding or
hematoma at the access site requiring transfusion, vascular
repair or external compression. Other bleeding complications
were defined as gastrointestinal, neurologic or any other
significant bleed other than that of the access site. Stent
restenosis was defined as $50% diameter stenosis at the
stented site or at the proximal or distal adjacent sites. Diffuse
restenosis was defined as a $50% luminal narrowing $10 mm
in length; if shorter, the restenosis was defined as focal (32,33).
Statistical analysis. The primary clinical analysis consisted
of a comparison between the two cohorts that were divided by
age. Categorical variables are presented as absolute numbers
(percent). Continuous variables are presented as mean val-
ues 6 standard deviation. Differences between groups were
evaluated by chi-square analysis for categorical data or the
two-tailed Student t test for continuous data. These differences
were considered statistically significant at p value #0.05. The
Kaplan-Meier method was used to generate a survival curve.
Abbreviations and Acronyms
atm 5 atmospheres
CABG5 coronary artery bypass grafting
EF 5 ejection fraction
IVUS 5 intravascular ultrasound
MLD 5 minimal lumen diameter
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
QCA 5 quantitative coronary angiography
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Results
Baseline clinical and cardiovascular characteristics.
These are shown for both cohort groups in Table 1. Average
age of the younger group was 58 6 2.9 years and 78 6 9.0 years
for the elderly group. There were significant differences in risk
factors between the two groups with the elderly having a higher
prevalence of hypertension (56% vs. 44%, p 5 0.0006), and the
younger group having a greater incidence of hypercholesterol-
emia (57% vs. 44%, p 5 0.003), family history (44% vs. 29%,
p 5 0.0005), and smoking (65% vs. 44%, p 5 0.0001). Left
ventricular ejection fraction was significantly different (58.4%
in the younger cohort vs. 54.4% in the older cohort, p 5
0.0001). There were much higher rates of unstable angina in
the elderly population (47% vs. 28%, p 5 0.0001). The only
major risk factor without a significant difference between the
two groups was incidence of diabetes mellitus (13% vs. 12%).
Angiographic and procedural characteristics. Baseline an-
giographic and procedural characteristics are shown in Table 2.
There was significantly more three vessel coronary disease
present in the elderly patients (40% vs. 24%, p 5 0.0001), and
a greater proportion of combined type B2 and C type lesions
(72% in the elderly vs. 65% in the younger, p 5 0.09). Also,
there were a higher proportion of calcified lesions in the
elderly group (30% vs. 13%, p 5 0.0001). Surprisingly, there
were a larger number of total occlusions in the younger cohort
(13% vs. 9%, p 5 0.04). There was no significant difference
between groups in angiographic mean reference diameter,
lesion percent stenosis and lesion length.
Stent implant procedure characteristics. Procedural char-
acteristics are seen in Table 3. Various stents were used in both
patient populations; however, a stent summary shows that
there is no significant difference between the two groups (p 5
0.5). The Palmaz-Schatz and the NIR stent were the most
commonly used during the course of this study. A combination
of different stent types were used in 7.7% of the younger group
and 9.4% of the older group (p 5 NS). There were some
significant differences between the groups as to which arteries
needed stenting. There were more LAD lesions stented in the
younger group (46% vs. 34%, p 5 0.0001) and more left main
stenting in the elderly (1.5% vs. 7.3%, p 5 0.0001). Frequency
of the various lesion sites treated also differed, with more ostial
lesions in the elderly (15% vs. 7%) and more proximal lesions
in the younger cohort (p 5 0.006). In accordance with the
presence of more multivessel disease, there was more multives-
sel stenting in the elderly (44% vs. 27%, p 5 0.0001). Overall
number of stents per patient, final balloon size and maximal
Table 1. Baseline Clinical Characteristics
Cohort , 75
(n 5 2,551)
Cohort $ 75
(n 5 137) p Value
Mean age, (years) 58 6 3 78 6 9 —
Risk factors, n (%)
Hypercholesterolemia 1,444 (57) 60 (44) 0.003
Family history 1,106 (44) 38 (29) 0.0005
Hypertension 1,113 (44) 76 (56) 0.006
Diabetes 337 (13) 17 (12) NS
Smoking history 1,614 (64) 60 (44) 0.0001
LVEF, % 58.4 6 11.3 54.4 6 11.7 0.0001
Prior MI, n (%) 1,132 (44) 64 (47) NS
Unstable Angina, n (%) 696 (28) 64 (47) 0.0001
CCS angina class, n (%) 0.0001
0 251 (10) 5 (4)
1 407 (16) 8 (6)
2 737 (30) 23 (17)
3 551 (22) 40 (29)
4 536 (22) 60 (44)
CCS 5 Canadian Cardiovascular Society classification; LVEF 5 left ven-
tricular ejection fraction; MI 5 myocardial infarction.
Table 2. Angiographic and Procedural Characteristics
Cohort , 75
(n 5 2,551)
Cohort $ 75
(n 5 137) p Value
Number of diseased vessels, n (%) 0.0001
1 965 (38) 30 (22)
2 962 (38) 52 (38)
3 600 (24) 55 (40)
Multivessel disease, n (%) 1,562 (62) 107 (78) 0.0001
Modified AHA/ACC lesion type, n (%) 0.002
A 116 (5) 2 (2)
B1 747 (30) 35 (26)
B2 1,050 (42) 77 (58)
C 562 (23) 19 (14)
Calcified lesions, n (%) 314 (13) 40 (30 0.0001
Bifurcation lesions, n (%) 598 (25) 42 (31) NS
Total occlusions, n (%) 317 (13) 9 (7) 0.04
Angio mean reference diameter (mm) 3.1 6 0.5 3.1 6 0.6 NS
Lesion % stenosis 72 6 15 71 6 14 NS
Lesion length (mm) 11.1 6 7 11.4 6 8 NS
AHA/ACC 5 American Heart Association/American College of Cardiology.
Table 3. Stent Implantation Procedure Characteristics
Cohort , 75
(n 5 2,551)
Cohort $ 75
(n 5 137) p Value
Artery stented, n (%) 0.0001
Left main 38 (1.5) 10 (7.3)
Left anterior descending 1,170 (46) 47 (34)
Right coronary artery 710 (28) 33 (24)
Left circumflex 404 (16) 28 (20)
Saphenous vein graft 65 (3) 4 (3)
Lesion site stented, n (%)
Ostial 170 (7) 20 (15)
Proximal 1,063 (42) 50 (36)
Mid 1,024 (40) 53 (39)
Distal 291 (11) 14 (10)
Multivessel stenting, n (%) 676 (27) 59 (44) 0.0001
Stents per patient, n (%) 2.3 6 1.6 2.5 6 1.5 NS
Final stent MLD (mm) 3.1 6 0.5 3.2 6 0.5 0.04
Final balloon size (mm) 3.7 6 2.5 3.6 6 0.5 NS
Maximal inflation pressure (atm) 16.1 6 3.3 16.0 6 3.4 NS
Adjunctive rotablation, n (%) 238 (9) 31 (23) 0.0001
Adjunctive DCA, n (%) 162 (6) 1 (.7) 0.007
Complete revascularization, n (%) 296 (56) 9 (31) 0.008
Procedure success, n (%) 2,379 (93) 122 (90) NS
DCA 5 directional coronary atherectomy.
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inflation pressure did not differ between groups. Final stent
MLD was slightly greater in the elderly by 0.1 mm (p 5 0.04).
More rotablation was performed in the elderly group (23% vs.
9%, p 5 0.0001), which goes along with the more calcified
disease. Complete revascularization was more readily achieved
in the younger group (56% vs. 31%, p 5 0.008); however,
procedure success did not differ significantly.
Primary clinical and angiographic events. These appear in
Table 4. Thrombotic events and bleeding complications did not
differ significantly between these groups. However, there were
significantly more procedural complications in the elderly,
including emergency coronary artery bypass grafting (CABG)
(3.7% vs. 1.4%, p 5 0.04) and procedural death (2.2% vs.
0.1%, p 5 0.0001).
Angiographic follow-up. Angiographic follow-up was ob-
tained in 73% of the ,75-year-old cohort and in 66% of the
$75-year-old cohort. Table 5 shows the results of angiographic
follow-up. Patients who had early events (within 5 months of
procedure), such as procedural CABG or death, are excluded.
Stent minimal lumen diameter (MLD) and percent stenosis
were significantly worse in the elderly group (2 mm vs. 1.8 mm,
p 5 0.03 and 33% vs. 41%, p 5 0.05). Restenosis rates were
higher in the elderly (47% vs. 28%, p 5 0.0007). Target lesion
revascularization reflected the restenosis rates and were higher
in the elderly (28% vs. 19%, p 5 0.02).
Clinical follow-up. Long-term clinical follow-up is reported
only in the elderly population and was obtained in 97% of
patients. The mean follow-up period was 12 months ranging
from within 1 month of procedure in cases of early adverse
events to 58 months poststenting. A Kaplan-Meier curve
demonstrates survival rate in this group with 91% of patients
being alive within the clinical follow-up period (Figure 1). The
event-free survival rate in the elderly during this period was
54% with an incidence of recurrent angina, revascularization,
MI or death in 46% of patients. Table 6 depicts a subanalysis
of elderly patients who died. There were 3 procedural deaths
and 7 deaths in the follow-up period. Average age of these
patients is 78.6 6 3.7 with an 80% incidence of unstable angina
and 60% incidence of prior MI in this subgroup. Average
ejection fraction is 45.6%. All patients had multivessel disease
and complex coronary lesions (B2 or C type). Of note is the
fact that none of the elderly patients in this subgroup was diabetic.
Also of interest is that of the 10 elderly patients who had
left main coronary artery stenting (8 being unprotected left
main arteries) 7 patients had angiographic follow-up without
restenosis. Of the remaining 3 patients, one had a procedural
complication (this was a CABG; no other procedural compli-
cations occurred), one patient was lost to follow-up and for the
final patient it was too early to obtain angiographic follow-up.
Discussion
Revascularization in the elderly: CABG and PTCA. The
majority of hospital admissions for cardiovascular disease
involve the elderly population. When undergoing revascular-
ization, this high-risk group has traditionally been reported to
have an increased rate of procedure-related death, MI, bleed-
ing complications and stroke versus younger patients (4–23).
Despite this, rates of revascularization in this population have
increased significantly since 1987 and several studies have
shown improving trends in elderly patients undergoing revas-
cularization. Also, patients $65 years of age postacute MI have
a 30-day mortality of 21% and a one-year mortality of 34%
(32) and studies such as Thrombolysis In Myocardial Infarc-
tion (TIMI) IIIB have shown improved outcome, at least in the
short term, in elderly patients undergoing aggressive revascu-
larization when presenting with unstable angina or non-Q w
MI (33).
Table 4. Clinical Events at One Month
Complications, n (%)
Cohort , 75
(n 5 2,551)
Cohort $ 75
(n 5 137) p Value
Acute stent thrombosis 12 (0.5) 1 (0.7) NS
Subacute stent thrombosis 20 (0.8) 3 (2.2) NS
Myocardial infarction 44 (1.7) 4 (2.9) 0.2
Emergency CABG 36 (1.4) 5 (3.7) 0.04
Procedural death 4 (0.12) 3 (2.2) 0.0001
Vascular complications 21 (0.9) 1 (0.8) NS
Other bleeding complications 19 (0.8) 2 (1.6) NS
CABG 5 coronary artery bypass grafting.
Table 5. Angiographic and Clinical Data at Follow-Up
Cohort , 75
(n 5 2,551)
Cohort $ 75
(n 5 137) p Value
Follow-up (%) 73 66 NS
Stent MLD (mm) 2 6 0.99 1.8 6 0.9 0.03
Mean reference diameter (mm) 2.99 6 0.6 2.94 6 0.5 NS
Stent percent stenosis 33 6 29 41 6 27 0.05
Restenosis, n (%) 451 (28) 32 (47) 0.0007
Type of restenosis, n (%) NS
focal 167 (56) 15 (54)
diffuse 133 (44) 13 (46)
TLR, n (%) 399 (19) 31 (28) 0.02
MLD 5 the minimal lumen diameter; TLR 5 target lesion revascularization.
Figure 1. Kaplan-Meier curve of survival poststent implantation for
patients 75 years of age or older. Adverse events occur early; overall
long-term survival rate for this group is 91%.
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Table 6. Demographic Data and Study Results of the 10 Deceased Elderly Patients
Patient Age/sex U/A Prior MI EF, %
Number of
Diseased Vessels Vessel
Lesion
Type
Number/
type stent
Balloon
size (mm)/
press (atm)
Reference
vessel
diam (mm)
MLD (mm)
pre/post Comments
1 77/M Yes No 40 2 LAD B2 3 PS 3.5/14 2.86 0.94/3.34 Death 5 months post procedure.
LAD B2 1 PS 4.0/16 3.43 1.30/3.62
2 77/F Yes Yes 55 3 LCx B2 2 PS 3.5/16 3.45 1.00/3.72 Procedural death.
LAD B2 1 AVE 3.5/16 3.45 1.00/3.81 Dissection, abrupt closure, EMD.
3 84/M Yes No 45 2 Diag B2 1 PS 3.5/20 3.00 1.59/— Procedural death.
RCA B2 1 PS 4.0/24 3.70 1.54/3.58 Vessel rupture, MI, CHF.
4 76/M Yes Yes 31 2 Diag B1 1 GR12 2.5/18 2.00 1.03/1.96 Death one month post procedure.
OM C 1 GR20 3.5/15 2.76 0.00/2.90 (Subacute stent thrombosis at 1 week)
5 77/M Yes Yes 50 3 RCA B2 1 AVE 4.0/16 3.00 1.19/3.07 Expired during mitral valve surgery/
RCA B1 1 PS 4.5/18 3.58 1.42/3.85 CABG 3 months post stenting.
6 87/M Yes Yes 30 3 LAD B2 1 Wiktor 3.50/12 2.81 1.35/2.76 Developed renal failure and died 8 days
post procedure.
7 77/F No No 60 2 RCA C 2 AVE 3.50/12 2.92 0.00/3.26 Acute stent thrombosis with subsequent
RCA B2 1 NIR 3.50/18 3.39 1.41/3.06 MI, renal failure and death 1 month
later.
8 76/F Yes Yes 40 2 LCx B2 2 PS 2.50/20 2.94 0.29/2.51 Sub-acute stent thrombosis and death 6
SVG B1 1 PS 4.50/11 4.23 1.18/4.50 days post stenting.
9 78/M No Yes 45 3 LAD B2 2 PS 3.75/14 2.65 1.20/— Procedural death. Balloon rupture with
subsequent arrhythmia, hypotension.
10 77/F Yes No 60 3 LAD B2 5 PS 3.50/18 2.61 1.27/2.85 Abrupt closure with emergency CABG
and death soon after surgery.
Mean 78.6 2/8 4/6 45.6 5/5 — — — 3.56/16 3.04 1.04/3.21
SD(6) 3.7 10.7 0.56/3.7 0.56 0.48/0.60
CABG 5 coronary artery bypass graft; CHF 5 congestive heart failure; Diag 5 diagonal; EF 5 ejection fraction; EMD 5 electrical mechanical dissociation; GR 5 Gianturco-Roubin; LAD 5 left anterior descending;
LCx 5 left circumflex; MI 5 myocardial infarction; MLD 5 minimal lumen diameter; OM 5 obtuse marginal; PS 5 Palmaz-Schatz; RCA 5 right coronary artery; SD 5 standard deviation; SVG 5 saphenous vein graft;
U/A 5 unstable angina. None of the above patients were diabetic.
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Recent studies regarding CABG in the elderly report
procedural mortality rates of 6% to 10% (1–5,15,16) and
30-day mortality of 8% to 14% (1,5). Roach et al. have shown
that patients over age 70 who underwent coronary bypass
surgery had a cumulative incidence of stroke of 12% (15). This
in turn was associated with a 5- to 10-fold increase in mortality.
There has also been extensive work examining the results of
angioplasty in the elderly. These reports exhibit procedural
mortality rates of 1.4% to 10% and an emergency CABG rate
ranging from 0.7% to 7%. Thompson et al. (6) have shown a
changing trend towards lower complication rates in the elderly
treated with PTCA between 1980 and 1992 with procedural
mortality decreasing to 1.4% and emergency CABG down to
0.7%.
Since the time of these early reports, the use of high-
pressure balloon inflations, intravascular ultrasound guidance
and better antiplatelet agents have contributed to the removal
of anticoagulation, bringing stenting to widespread use (24–
26). Although there is an extensive amount of published
information regarding PTCA and CABG in the elderly, there
are limited data available with regards to stenting in this
population.
Coronary artery stenting in the elderly. Early studies of
stenting and standard anticoagulation reported significant vas-
cular complications at a rate of about 16% (34). Vascular
complications were even more pronounced in the elderly;
Elliot et al. showed a 45% vascular complication rate for
patients .70 years of age who underwent stenting (22).
Removal of anticoagulation has tempered this situation. A
recent analysis that compared vascular complications from two
different time periods (1991–1994 vs. 1994–1995) in patients
.70 years of age who underwent Palmaz-Schatz stent implan-
tation showed an incidence of vascular complications of 13.2%
and 0%, respectively (35). Our data, with the new antiplatelet
regimen, show a vascular complication rate of 0.8% in the
population $75 and 0.9% in the patients ,75 (p 5 NS). In this
regard we have been able to reduce what was a severe problem,
and to equalize the complication rate between older and
younger patients.
However, there are a number of problems that continue to
exist with revascularization in the elderly population. Our
results show a promising trend toward better outcome in this
fragile group, but a significant difference continues to exist
between results obtained in the older versus younger patients,
both in short- and long-term outcome. There was a signifi-
cantly higher rate of procedure-related CABG and death along
with substantially more procedural myocardial infarction in the
$75 cohort (Table 4). Also of concern in treating this elderly
group is the fact that there is a much higher rate of angio-
graphic restenosis (47% vs. 28%, p 5 0.0007). The TLR
coincides with these results and has a concurrent distribution
of events (28% vs. 19%, p 5 0.02). Significant differences in the
elderly population that help to explain their inferior outcome
include the fact that they present with lower ejection fractions,
more unstable angina and a higher angina class (Table 1). It
has also been documented in previous studies that older
patients present with more comorbid disease (5). The angio-
graphic lesion characteristics we found also provide an expla-
nation for higher complication rates and worse long-term
outcome. There were more ostial lesions (15% vs. 7%, p 5
0.006), three-vessel disease, calcified lesions and complex
lesions (72% combined B2 and C type lesions vs. 65%, p 5
0.09) in the elderly compared to the younger patients. Treat-
ment strategies did not differ greatly as average balloon size
and inflation pressure were similar (Table 3). Likewise, angio-
graphic reference diameters and lesion percent stenosis
showed no significant difference (Table 2). The approach
differed on the basis of adjunctive procedures and complete
revascularization. More rotablation was performed in the older
group (23% vs. 9%, p 5 0.0001) reflecting the fact that there
was a proportionately higher number of calcified lesions (30%
vs. 13%, p 5 0.0001). Complete revascularization was more
often achieved in the younger cohort although procedure
success was not significantly different (Table 3). This reflects
the fact that there was more three-vessel disease in the elderly
(Table 2), making complete revascularization more difficult to
achieve.
These clinical and angiographic characteristics in the el-
derly may also help explain the fact that long-term clinical
follow-up shows a high incidence of adverse events. However,
despite the higher rates of procedural complications, restenosis
and low rate of freedom from events, the elderly group displays
a good overall survival rate on clinical follow-up post stent
implantation (Figure 1).
Elderly patients with poorest outcome. A subgroup analy-
sis of the 10 elderly patients who died during or following stent
implantation yields some interesting results. Three deaths were
considered procedural; five deaths were within 1 month, with
one death at 3 months and one death at 5 months. Therefore,
8 of the 10 deaths were within 1 month of stent implant and all
deaths were within 5 months of procedure. It seems that if an
elderly patient survived this critical period, he could expect
long-term survival. The findings that set this group apart from
the rest of the elderly population and portend poorer outcome
include some of the classic risk factors. Five risk factors
including unstable angina, prior MI, lower ejection fraction
(,50%), multivessel disease and complex lesions were all
much more prominent in this subgroup compared to the rest of
the elderly. In fact, 8 of the 10 patients who died had $4 of
these risk factors; the two remaining patients had either two or
three of these characteristics. The total number of elderly
patients with $4 of these risk factors is 26; therefore, the
mortality for an elderly patient with these characteristics
undergoing coronary artery stenting was 31%.
Limitations of the study. There are several limitations to
the present study. It is a retrospective study and therefore
inherently contains all the disadvantages of such a comparative
analysis. In making any direct comparisons, lesion character-
istics and number do differ in some respects between the
elderly and younger populations and treatment strategies
towards these lesions vary slightly. However, this is part of
what we wished to demonstrate; that the elderly do present
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with more difficult lesions and that this plays some role in their
poorer outcome. Angiographic follow-up in the elderly popu-
lation was slightly lower than in the younger group (66% vs.
73%, p 5 NS); however, a 66% follow-up in this fragile
population is a realistic target. Validity of the observed angio-
graphic restenosis rates in the elderly population is supported
by the strong correlation between these results, the TLR and
the clinical event rate (restenosis 47%, TLR 28% and clinical
follow-up event rate of 46%). This study does represent a
relatively large nonselected experience from a single center,
which provides some insight into the difficulties that exist with
revascularization and stent implantation in the elderly popu-
lation.
Conclusions. Elderly patients who undergo coronary artery
stenting have significantly more procedural complications and
worse 6-month outcome than younger patients. This is in part
due to presentation of the elderly with significantly more
three-vessel coronary artery disease, unstable angina, complex
lesions and lower ejection fractions. The subgroup of elderly
patients with poorest outcome had significantly higher rates of
these combined risk factors, including prior MI. Overall long-
term survival after coronary artery stenting in the elderly is
91% at 1 year but event free survival is only 54%. There have
been considerable gains made in the past 10 years in the
treatment of coronary artery disease in the elderly; however,
despite technological advances with improvements in revascu-
larization equipment, increased operator experience, proce-
dural modifications and stent technology, procedural compli-
cations and adverse cardiac events during follow-up are
significantly higher in older patients. Further improvements
are necessary to optimize the results in this high-risk group.
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